PMID- 31957851
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20210101
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 24
IP  - 1
DP  - 2020 Jan
TI  - CircRNA 010567 improves myocardial infarction rats through inhibiting TGF-beta1.
PG  - 369-375
LID - 19935 [pii]
LID - 10.26355/eurrev_202001_19935 [doi]
AB  - OBJECTIVE: To observe the intervention effect of circular ribonucleic acid 
      (circRNA) 010567 on myocardial infarction (MI)-induced myocardial fibrosis (MF) 
      in rats, and to explore whether its mechanism of action is related to the 
      regulation on the transforming growth factor-beta1 (TGF-beta1) signaling pathway. 
      MATERIALS AND METHODS: The rat model of acute MI was established using ligation 
      of the left anterior descending coronary artery. Model rats were randomly divided 
      into circRNA 010567 siRNA group and Model group, with sham operation group as 
      Control group. The effects of circRNA 010567 on the cardiac function, MF, 
      myocardial apoptosis, mRNA, and protein expression levels of TGF-beta1 and Smad3 in 
      heart tissues of MI rats were detected using the small animal ultrasound system, 
      Masson staining, terminal deoxynucleotidyl transferase-mediated dUTP nick end 
      labeling (TUNEL) staining, reverse transcription-polymerase chain reaction 
      (RT-PCR), and Western blotting, respectively. RESULTS: Compared with Control 
      group, Model group had significantly decreased cardiac function, significantly 
      lower left ventricular ejection fraction (LVEF), and left ventricular fractional 
      shortening (LVFS), markedly increased left ventricular end-diastolic diameter 
      (LVDd), and left ventricular end-systolic diameter (LVDs), severe MF, as well as 
      a significantly higher apoptosis rate of myocardial cells, and evidently 
      increased mRNA and protein levels of TGF-beta1 and Smad3 in heart tissues. Compared 
      with Model group, circRNA 010567 siRNA group had evidently improved cardiac 
      function, significantly higher LVEF and LVFS, markedly decreased LVDd and LVDs, 
      alleviated MF, a significantly lower apoptosis rate of myocardial cells, and 
      evidently decreased mRNA and protein levels of TGF-beta1 and Smad3 in heart tissues. 
      CONCLUSIONS: CircRNA 010567 siRNA can improve the cardiac function, alleviate the 
      MF, and inhibit the myocardial apoptosis, thereby further suppressing MI-induced 
      MF, whose mechanism may be related to the inhibition on the TGF-beta1 signaling 
      pathway.
FAU - Bai, M
AU  - Bai M
AD  - Heart Center, the First Affiliated Hospital of Lanzhou University, Lanzhou, 
      China. baiming@vip.163.com.
FAU - Pan, C-L
AU  - Pan CL
FAU - Jiang, G-X
AU  - Jiang GX
FAU - Zhang, Y-M
AU  - Zhang YM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (RNA, Circular)
RN  - 0 (RNA, Messenger)
RN  - 0 (Transforming Growth Factor beta1)
SB  - IM
MH  - Acute Disease
MH  - Animals
MH  - Apoptosis
MH  - Disease Models, Animal
MH  - Male
MH  - Myocardial Infarction/*metabolism/pathology
MH  - RNA, Circular/*metabolism
MH  - RNA, Messenger/genetics/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Signal Transduction
MH  - Transforming Growth Factor beta1/genetics/*metabolism
EDAT- 2020/01/21 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/01/21 06:00
PHST- 2020/01/21 06:00 [entrez]
PHST- 2020/01/21 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
AID - 19935 [pii]
AID - 10.26355/eurrev_202001_19935 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2020 Jan;24(1):369-375. doi: 
      10.26355/eurrev_202001_19935.